Soleno Therapeutics' Vykat XR has become the first FDA-approved treatment for excessive eating in rare disorder Prader-Willi syndrome.

The FDA has set a goal date of Aug. 27, 2025. If approved, the therapy would be branded as Lytenava and be the first ...

A new paper by the Institute for Clinical and Economic Review (ICER) looks at the cost-effectiveness versus affordability issue of obesity medications such as Wegovy and Zepbound.

Amvuttra (vutrisiran) Transthyretin-directed small interfering RNA therapeutic Treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce ...

Eli Lilly CEO David Ricks to the BBC: “It feels like it'll be hard to come back from here." The U.S. pharmaceutical industry is bracing for a possible wave of tariffs on foreign-made drugs, even as ...

Amvuttra (vutrisiran) Transthyretin-directed small interfering RNA therapeutic Treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce ...

Approval was based on results from the Phase III ALIGN study, which demonstrated a significant reduction in proteinuria at 36 weeks in patients with primary immunoglobulin A nephropathy. Results from ...

Věděli jste, proč je důležité agresorovi vykat a jak naše ruce dokážou vyřešit až 90 % konfliktů? Instruktorka také ukázala, které obranné prostředky skutečně fungují a které ne. Jak šli základy ...